CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma

Cancer Immunology, Immunotherapy

Volumn 61, Issue 4, 2012, Pages 561-571

  Hong, Sungyoul ^a   Qian, Jianfei ^a   Li, Haiyan ^a   Yang, Jing ^a   Lu, Yong ^a   Zheng, Yuhuan ^a   Yi, Qing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvants; Idiotype; Immunotherapy; Multiple myeloma; Vaccination

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN IDIOTYPE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ERADICATION THERAPY; HUMORAL IMMUNITY; MEMORY T LYMPHOCYTE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN IDIOTYPES; INTERFERON-ALPHA; MICE; MULTIPLE MYELOMA; OLIGODEOXYRIBONUCLEOTIDES; VACCINATION;

EID: 84862279850     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1123-2     Document Type: Article

References (44)

1. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046-1060
2. Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111(6):2962-2972
3. Yi Q (2009) Novel immunotherapies. Cancer J 15(6):502-510
4. Yi Q (2003) Immunotherapy in multiple myeloma: current strategies and future prospects. Expert Rev Vaccines 2(3):391-398
5. Houot R, Levy R (2009) Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 23(3):137-142
6. Wang S, Hong S, Wezeman M, Qian J, Yang J, Yi Q (2007) Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Front Biosci 12:3566-3575
7. Dubensky TW Jr, Reed SG (2010) Adjuvants for cancer vaccines. Semin Immunol 22(3):155-161
8. Bergenbrant S, Yi Q, Osterborg A, Bjorkholm M, Osby E, Mellstedt H, Lefvert AK, Holm G (1996) Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 92(4):840-846 (Pubitemid 26109498)
9. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Ruden U, Lefvert AK, Holm G, Mellstedt H (1998) Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91(7):2459-2466 (Pubitemid 28155521)
10. Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H (2007) Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 13(5):1503-1510 (Pubitemid 46450441)
11. Garrett IR, Dallas S, Radl J, Mundy GR (1997) A murine model of human myeloma bone disease. Bone 20(6):515-520 (Pubitemid 27270464)
12. Mundy G (2001) Preclinical models of bone metastases. Semin Oncol 28(11):2-8
13. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R (2000) Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 6(6):621-627
14. Kwak LW, Young HA, Pennington RW, Weeks SD (1996) Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93(20):10972-10977 (Pubitemid 26333102)
15. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q (2002) Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99(9):3280-3285 (Pubitemid 34525308)
16. Hong S, Qian J, Yang J, Li H, Kwak LW, Yi Q (2008) Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res 68(20):8456-8464
17. Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A (1999) Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94(2):673-683 (Pubitemid 29323881)
18. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5(10):1171-1177 (Pubitemid 29474422)
19. Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH (2005) Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11(9):986-991 (Pubitemid 41294445)
20. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF (2001) Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14(4):461-470 (Pubitemid 32441598)
21. Steinman RM, Hemmi H (2006) Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311:17-58 (Pubitemid 47413194)
22. Marrack P, Kappler J, Mitchell T (1999) Type I interferons keep activated T cells alive. J Exp Med 189(3):521-530
23. Zhang X, Sun S, Hwang I, Tough DF, Sprent J (1998) Potent and selective stimulation of memory-phenotype CD8 + T cells in vivo by IL-15. Immunity 8(5):591-599 (Pubitemid 28264750)
24. Cho HJ, Hayashi T, Datta SK, Takabayashi K, Van Uden JH, Horner A, Corr M, Raz E (2002) IFN-alpha beta promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol 168(10):4907-4913 (Pubitemid 34495952)
25. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali- Krishna K (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202(5):637-650 (Pubitemid 41248415)
26. Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW (2009) IFN-alpha enhances peptide vaccineinduced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 182(12):7398-7407
27. Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L (2006) Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 66(9):4943-4951
28. Gutterman JU (1994) Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 91(4):1198-1205
29. Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O'Connell MJ, Oken MM, Borden EC (1992) Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327(19):1336-1341
30. Schaar CG, Kluin-Nelemans HC, Te Marvelde C, le Cessie S, Breed WP, Fibbe WE, van Deijk WA, Fickers MM, Roozendaal KJ, Wijermans PW (2005) Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol 16(4):634-639 (Pubitemid 40613331)
31. Blade J, San Miguel JF, Escudero ML, Fontanillas M, Besalduch J, Gardella S, Arias J, Garcia-Conde J, Carnero M, Marti JM, Rozman C, Estape J, Montserrat E (1998) Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the study and treatment of hematological malignancies, Spanish Society of Hematology). Leukemia 12(7):1144-1148 (Pubitemid 28349812)
32. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522):546-549
33. Shirota H, Sano K, Hirasawa N, Terui T, Ohuchi K, Hattori T, Shirato K, Tamura G (2001) Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 167(1):66-74 (Pubitemid 32567762)
34. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM (1996) CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93(7):2879-2883 (Pubitemid 26116242)
35. Sun S, Zhang X, Tough DF, Sprent J (1998) Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 188(12):2335-2342 (Pubitemid 29028505)
36. Stacey KJ, Sweet MJ, Hume DA (1996) Macrophages ingest and are activated by bacterial DNA. J Immunol 157(5):2116-2122 (Pubitemid 126449689)
37. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM (1997) Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94(20):10833-10837
38. Gendron KB, Rodriguez A, Sewell DA (2006) Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice. Arch Otolaryngol Head Neck Surg 132(3):327-332
39. Mukherjee P, Pathangey LB, Bradley JB, Tinder TL, Basu GD, Akporiaye ET, Gendler SJ (2007) MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine 25(9):1607-1618 (Pubitemid 46108207)
40. Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO (2000) Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 19(4-5):530-537
41. Radl J, De Glopper ED, Schuit HR, Zurcher C (1979) Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 122(2):609-613 (Pubitemid 9089221)
42. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K (2000) The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 1(5):351-356
43. Ballas ZK, Rasmussen WL, Krieg AM (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157(5):1840-1845 (Pubitemid 126449654)
44. Halpern MD, Kurlander RJ, Pisetsky DS (1996) Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol 167(1):72-78 (Pubitemid 26048848)